Bronchitis Treatment Market Is Expected To Reach US$ 4,606.3 Mn By 2026 | Credence Research

Posted December 30, 2019 by johnsonpaul

The global market for Bronchitis Treatment was valued at USD 3.345.8 million in 2017 and is expected to reach USD 4.606.3 million by 2026, increasing to CAGR by 4.9 percent from 2018 to 2026.

According to the latest report published by Credence Research, Inc. “Bronchitis Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2018-2026,” the global market for Bronchitis Treatment was valued at USD 3.345.8 million in 2017 and is expected to reach USD 4.606.3 million by 2026, increasing to CAGR by 4.9 percent from 2018 to 2026.

Browse Full Report at

Market Insights

Bronchitis is one of the most common respiratory diseases seen in both developed and developing countries. Chronic bronchitis is life-threatening most of the time, and the Centers for Disease Control and Prevention reported that 8.6 million people were diagnosed with chronic bronchitis in the U.S. in 2016 with 0.2 percent mortality.

However, as the U.S. is a more developed country, the mortality rate is low, but in developing and underdeveloped countries the mortality rate is between 3% and 4%. Bronchitis is caused by several common factors such as cold & flu and other bacterial infections that lead to airway obstruction due to inflammation of the bronchial walls. Patients with acute bronchitis take 1 to 2 weeks to recover, while chronic bronchitis takes 2 to 3 months to recover. However, the overall drug treatment pipeline for bronchitis is strong due to the presence of several combination therapies that provide target-specific performance.

Bronchodilators were identified as the largest growing segment in the bronchitis treatment market in 2017 due to key factors such as increasing bronchitis-related prevalence and increasing awareness campaigns related to chronic bronchitis and other bacterial infections in developed and developing countries. The awareness-raising activities carried out in developing and developed countries have helped to increase the rate of diagnosis in the last few years. Bronchodilators are always the first-line drugs for the treatment of bronchitis, as clearing the airway obstruction is the most important thing in chronic bronchitis to ease the patient's breathing.

North America has been identified as the largest bronchitis treatment market due to rising prevalence coupled with high bronchitis prevalence, and an increasing trend in young people's smoking has contributed to a slight increase in prevalence, advanced and accessible diagnostic technologies. According to Pharmaprix, about 1 in 20 people in North America suffer from chronic bronchitis. In addition, the market for bronchitis in North America is also growing due to ongoing developments in research into the treatment of bronchitis by the drug pipeline.

Browse Full Report at

Market Competition Assessment:

The bronchitis treatment market is growing steadily and major companies operating in this market are developing treatments that are safe and target-specific. The major companies available in the global market are AstraZeneca Plc, DBV Technologies SA, F. Hoffmann-La Roche Ltd., Han Wha Pharma Co. Ltd., and Mucosis BV among others.

Key Market Movements:

Rising awareness and prevalence related to bronchitis treatment & diagnosis expected to assist the market growth
Incessant growth in research & development of bronchitis treatment will assist the growth in demand for safe & efficient treatment options
Mounting diagnosis rate related to developing countries will increase the demand for bronchitis treatment market
Strong drug pipeline expected to increase the CAGR of the overall market in the near future
You can get the sample copy of this research by Credence Research here:

Key research study highlights comprise:

Exhaustive research and analysis of the global bronchitis treatment industry
The key market segments along have been explained in the report thoroughly along with their existing and estimated market size
Major elements of market dynamics such as drivers, challenges and opportunities and their effect on bronchitis treatment market are also covered in the report
Key players operating in the market are profiled and accompanied by the competitive landscape evaluated on the basis of product offering & business strength
Cross-sectional analysis of each region covering individual segments for the forecast period 2018 - 2026 in terms of value (US$Mn)

The participants tracked for primary interviews include:

Marketing/product managers
Vice President/ CEOs
National sales managers
Market intelligence managers
Purchasing man
Market Segmentation

By Type of Drug Class

Beta-adrenergic agonist
Systemic corticosteroids
Inhaled corticosteroids
Phosphodiesterase-4 inhibitors

By Pipeline Analysis

Phase III
Combination Product: Extracorporeal Photopheresis (ECP)

By Geography Segment

North America (the U.S., Rest of North America)
Europe (U.K., Germany, France, Rest of Europe)
Asia Pacific (China, Japan, India, Rest of Asia Pacific)
Rest of the World (the Middle East & Africa, Latin America)

Blog Medium:
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Chris Smith
Phone +1-800-361-8290
Business Address 105 N 1st ST #429, SAN JOSE, CA 95103, United States
CA 95103, United States
Country United States
Categories Business , Industry , Research
Tags Bronchitis Treatment market
Last Updated December 30, 2019